Namodenoson Treatment of Advanced Pancreatic Cancer
Trial details
- Registry ID
- NCT06387342
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as CF102
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Namodenoson Treatment of Advanced Pancreatic CancerNCT06387342 | Can-Fite BioPharma | Phase 2 | Recruiting | 2026-07-15Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |